A. Keramopoulos

发表

The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas.

I. Giannopoulou, E. Mylona, A. Kapranou, 2007, Cancer letters.

Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer

V. Koika, G. Adonakis, N. Georgopoulos, 2006, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Overexpression of Cyclooxygenase-2 Is Associated with a Favorable Prognostic Phenotype in Breast Carcinoma

I. Papadaki, I. Giannopoulou, E. Mylona, 2005, Pathobiology.

High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma.

E. Patsouris, S. Theocharis, G. Tsourouflis, 2017, Neoplasma.

Effect of different ERK2 protein localizations on prognosis of patients with invasive breast carcinoma

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Study of phospho-β-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome

I. Papadaki, N. Kavantzas, I. Giannopoulou, 2006, Modern Pathology.

Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.

I. Papadaki, N. Kavantzas, I. Giannopoulou, 2006, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Lymphatic and blood vessel morphometry in invasive breast carcinomas: relation with proliferation and VEGF-C and -D proteins expression.

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2007, Histology and histopathology.

An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2013, Histopathology.

The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer

A. Lazaris, I. Giannopoulou, S. Markaki, 2004, Journal of Clinical Pathology.

Germline mutations in a clinic-based series of pregnancy associated breast cancer patients

M. Dimopoulos, S. Marinopoulos, A. Keramopoulos, 2021, BMC cancer.

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

D. Yannoukakos, H. Gogas, C. Markopoulos, 2008, Breast Cancer Research and Treatment.

Evaluation of Numeric Alterations of Chromosomes 1 and 17 by In Situ Hybridization in Invasive Breast Carcinoma With Clinicopathologic Parameters

I. Giannopoulou, A. Keramopoulos, L. Nakopoulou, 2002, Applied immunohistochemistry & molecular morphology : AIMM.

Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer

N. Pavlidis, C. Papadimitriou, C. Papadimitriou, 2001, Cancer investigation.

The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1‐MMP) and MMP‐9 according to their localization in invasive breast carcinoma

E. Mylona, A. Keramopoulos, L. Nakopoulou, 2007, Histopathology.

The multifunctional role of the immunohistochemical expression of MMP‐7 in invasive breast cancer

E. Mylona, A. Kapranou, J. Mavrommatis, 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.

I. Giannopoulou, E. Mylona, S. Markaki, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.

N. Pavlidis, C. Papadimitriou, G. Fountzilas, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Pregnancy and offspring after the appearance of breast cancer.

A. Keramopoulos, G. Stathopoulos, S. Vassilaros, 1997, Oncology.

Effect of estrogen receptor modulator tamoxifen on blood pressure, plasma renin activity, and renal sodium excretion.

G. Stergiou, A. Keramopoulos, A. S. Zourbaki, 2002, American journal of hypertension.

bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining.

A. Lazaris, P. Davaris, I. Giannopoulou, 1999, Histopathology.

Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2006, Journal of Clinical Pathology.

Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.

I. Giannopoulou, E. Mylona, S. Markaki, 2006, Cancer detection and prevention.

Expression patterns of β-catenin in in situ and invasive breast cancer

A. Keramopoulos, L. Nakopoulou, M. Pignatelli, 2001 .

Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype

Eleni Mylona, Ioanna Giannopoulou, I. Giannopoulou, 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Abnormal α‐catenin expression in invasive breast cancer correlates with poor patient survival

I. Giannopoulou, A. Keramopoulos, L. Nakopoulou, 2002 .

Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer

K. Kyriacou, D. Yannoukakos, A. Hadjisavvas, 2004, BMC Cancer.

The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma.

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2007, Gynecologic oncology.

The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases‐1 protein overexpression in breast cancer cells

A. Lazaris, I. Giannopoulou, S. Markaki, 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer

M. Dimopoulos, P. Athanassiades, A. Keramopoulos, 1998, Oncology.

DNA Topoisomerase II-Alpha Immunoreactivity as a Marker of Tumor Aggressiveness in Invasive Breast Cancer

P. Athanassiadou, A. Lazaris, N. Kavantzas, 2000, Pathobiology.

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients

G. Kouraklis, E. Patsouris, S. Theocharis, 2018, Pathology & Oncology Research.

Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome

I. Giannopoulou, E. Mylona, S. Markaki, 2006, Breast Cancer Research.

Expression patterns of beta-catenin in in situ and invasive breast cancer.

A. Keramopoulos, L. Nakopoulou, M. Pignatelli, 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Correlation of Tissue Inhibitor of Metalloproteinase-2 with Proliferative Activity and Patients’ Survival in Breast Cancer

I. Giannopoulou, J. Mavrommatis, A. Keramopoulos, 2002, Modern Pathology.

Pregnancy and offspring after the appearance of breast cancer

A. Keramopoulos, G. Stathopoulos, S. Vassilaros, 1996 .

Scintimammographic findings of in situ ductal breast carcinoma in a double-phase study with Tc-99m(V) DMSA and Tc-99m MIBI value of Tc-99m(V) DMSA.

A. Keramopoulos, S. Michalas, M. Sotiropoulou, 2000, Clinical nuclear medicine.

Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival.

I. Giannopoulou, A. Keramopoulos, L. Nakopoulou, 2002, Histopathology.

Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.

A. Scorilas, A. Keramopoulos, J. Yotis, 1993, Anticancer research.

PPARγ expression in breast cancer: clinical value and correlation with ERβ

I. Papadaki, I. Giannopoulou, E. Mylona, 2005, Histopathology.

Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer

A. Keramopoulos, G. Vourli, C. Dimitrakakis, 2005, Climacteric : the journal of the International Menopause Society.

Phytoestrogen supplementation: a case report of male breast cancer

A. Keramopoulos, L. Gosselink, C. Dimitrakakis, 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Stromelysin-3 Protein Expression in Invasive Breast Cancer: Relation to Proliferation, Cell Survival and Patients’ Outcome

Ioanna Giannopoulou, P. Athanassiadou, I. Giannopoulou, 2002, Modern Pathology.

99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI

A. Keramopoulos, S. Michalas, M. Sotiropoulou, 2001, European Journal of Nuclear Medicine.

c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.

A. Scorilas, A. Keramopoulos, J. Yotis, 1995, Anticancer research.

Lymphatic and blood vessel morphometry in invasive breast carcinomas: relation with proliferation and VEGF-C and -D proteins expression.

I. Giannopoulou, E. Mylona, A. Keramopoulos, 2007, Histology and histopathology.